Citation Information :
Oommen S, Pillai PS, Arivandakshan R, Nair K, Nair S. What is happening to our Pseudomonas? Trends of susceptibilities of culture-confirmed Pseudomonas aeruginosa infections in a tertiary care hospital. 2015; 17 (2):75-80.
Background and Objectives: Infections due to Pseudomonas aeruginosa, especially healthcare-associated infections, present a significant health problem worldwide. Drug resistance especially multidrug resistance in P. aeruginosa is on the rise. Thus the objective of this study was to determine the sensitivity pattern among clinical isolates obtained from the patients admitted to a tertiary care centre.
Materials and Methods: A total of 484 non-duplicate P. aeruginosa isolates in 2014, 444 isolates in 2013, 350 isolates in 2012 and 460 isolates in 2007 were characterized according to their antibiotic susceptibility, and the trends over time were analyzed.
Results: There were statistically significant increases in sensitivities of isolates P. aeruginosa from 2007 to 2014 to most of the routinely used antibiotics including Ciprofloxacin.
Conclusions: A detailed genomic- and/or proteomic-level study for our isolates is much desired to understand this loss of resistance so that the same may be replicated in other bacteria.
Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079-81.
National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Dolan R, Bennett JE, editors. Principles and Practices of Infectious Diseases. New York, NY: Churchill Livingstone; 1995. p. 1820-2003.
Todar K. Todar's Online Textbook of Microbiology. Madison: University of Wisconsin; 2014. Available at textbook of bacteriology.net/pseudomonas.html [Last accessed on 2015 Oct 16].
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003;289:885-8.
Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-21.
Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact. Antimicrob Agents Chemother 2006;50:43-8.
Landman D, Bratu S, Kochar S, Panwar M, Trehan M, Doymaz M, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007;60:78-82.
Mohanasoundaram KM. The antimicrobial resistance pattern in the clinical isolates of pseudomonas aeruginosa in a tertiary care hospital; 2008-2010 (A 3 Year Study). J Clin Diagn Res 2011;5:491-4.
Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582-610.
Ojala V, Laitalainen J, Jalasvuori M. Fight evolution with evolution: Plasmid-dependent phages with a wide host range prevent the spread of antibiotic resistance. Evol Appl 2013;6:925-32.
Murugan N, Malathi J, Umashankar V, Madhavan HN. Comparative genomic analysis of multidrug-resistant Pseudomonas aeruginosa clinical isolates VRFPA06 and VRFPA08 with VRFPA07. Genome Announc 2014;2. Pii: e00140-14.
DeNap JC, Hergenrother PJ. Hergenrother. Bacterial death comes full circle: Targeting plasmid replication in drug-resistant bacteria. Org Biomol Chem 2005;3:959-66.
